Overview

Growth of $10,000

10-year period ended 03/31/2016

  • Class A at NAV

Historic Returns (%)as of Mar 31, 2016

Annualized
1 Mo. 3 Mos. YTD 1 Yr. 3 Yrs. 5 Yrs. 10 Yrs.
04/30/2016
Fund at NAV 3.45 3.26 -8.20 -6.74 15.62 14.90 10.61
Fund w/Max Sales Charge -2.46 -2.72 -13.49 -12.12 13.35 13.55 9.96
MSCI World Health Care Index1 3.31 4.50 -3.74 -5.14 11.59 13.62 8.51
03/31/2016
Fund at NAV 2.49 -11.26 -11.26 -11.74 15.51 15.50 10.00
Fund w/Max Sales Charge -3.42 -16.38 -16.38 -16.79 13.25 14.15 9.35
MSCI World Health Care Index1 2.43 -6.82 -6.82 -8.28 11.85 14.45 8.14
Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund's current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative. Max Sales Charge: 5.75%.

Fund Factsas of Apr 30, 2016

Class A Inception 07/26/1985
Investment Objective Long-term capital growth
Total Net Assets $1.5B
Minimum Investment $1000
Expense Ratio2 1.44%
CUSIP 277902813

Top 10 Holdings (%)3,4as of Mar 31, 2016

Ono Pharmaceutical Co Ltd
Allergan plc
HCA Holdings Inc
AbbVie Inc
Intuitive Surgical Inc
Bristol-Myers Squibb Co
Boston Scientific Corp
Amgen Inc
Regeneron Pharmaceuticals Inc
Biogen Inc
Total 46.62

Portfolio Management

Samuel D. Isaly Managed Fund since 1989
Sven H. Borho, CFA Managed Fund since 2005
Geoffrey C. Hsu, CFA Managed Fund since 2005
Richard D. Klemm, Ph.D., CFA Managed Fund since 2005
Trevor M. Polischuk, Ph.D. Managed Fund since 2005

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding. Fund invests in an affiliated investment company (Portfolio) with the same objective(s) and policies as the Fund. References to investments are to the Portfolio's holdings.

About Risk 

Fund performance is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, established companies. No Fund is a complete investment program and you may lose money investing in a Fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.


Performance

Historic Returns (%)as of Mar 31, 2016

Annualized
1 Mo. 3 Mos. YTD 1 Yr. 3 Yrs. 5 Yrs. 10 Yrs.
04/30/2016
Fund at NAV 3.45 3.26 -8.20 -6.74 15.62 14.90 10.61
Fund w/Max Sales Charge -2.46 -2.72 -13.49 -12.12 13.35 13.55 9.96
MSCI World Health Care Index1 3.31 4.50 -3.74 -5.14 11.59 13.62 8.51
Morningstar™ Health Category5 3.45 3.80 -10.54 -10.35 14.95 15.41 10.77
03/31/2016
Fund at NAV 2.49 -11.26 -11.26 -11.74 15.51 15.50 10.00
Fund w/Max Sales Charge -3.42 -16.38 -16.38 -16.79 13.25 14.15 9.35
MSCI World Health Care Index1 2.43 -6.82 -6.82 -8.28 11.85 14.45 8.14
Morningstar™ Health Category5 3.20 -13.53 -13.53 -15.44 15.03 16.17 10.01
Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund's current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative. Max Sales Charge: 5.75%.

Calendar Year Returns (%)

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Fund at NAV -0.01 6.49 -7.24 9.89 11.13 4.75 15.49 44.56 27.39 8.39
MSCI World Health Care Index1 10.47 3.94 -21.50 18.89 2.41 9.46 17.54 36.27 18.10 6.60

Fund Facts

Expense Ratio2 1.44%
Class A Inception 07/26/1985
Distribution Frequency Annually

Risk Measures (3 Year)6as of Apr 30, 2016

Alpha (%) 1.80
Beta 1.20
R-Squared (%) 83.85
Standard Deviation (%) 15.62
Sharpe Ratio 1.00

Morningstar™ Ratingsas of Apr 30, 2016

Time Period Rating Rating (Load Waived) Funds in
Health
Category
Overall *** *** 124
3 Years *** *** 124
5 Years ** *** 116
10 Years *** *** 95
Based on Risk-Adjusted Returns.

The Overall Morningstar Rating for a fund is derived from a weighted average of the performance figures associated with its 3-, 5- and 10-year (if applicable) Morningstar Rating metrics.

© 2015 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers is responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating™ based on how a fund ranks on a Morningstar Risk-Adjusted Return measure against other funds in the same category. This measure takes into account variations in a fund's monthly performance after adjusting for sales loads (except for load-waived A shares) redemption fees, and the risk-free rate, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. Load-waived A share star ratings do not include any front-end sales load and are intended for those investors who have access to such purchase terms (e.g., plan participants of a defined contribution plan). Not all A share mutual funds for which Morningstar calculates a load-waived A share star rating may actually waive their front-end sales load. Therefore, Morningstar strongly encourages investors to contact their investment professional to determine whether they are eligible to purchase the A share without paying the front load. The Morningstar Rating may differ among share classes of a mutual fund as a result of different sales loads and/or expense structure.

NAV History

Date NAV NAV Change
May 25, 2016 $11.28 $0.03
May 24, 2016 $11.25 $0.18
May 23, 2016 $11.07 -$0.01
May 20, 2016 $11.08 $0.12
May 19, 2016 $10.96 -$0.09
May 18, 2016 $11.05 $0.04
May 17, 2016 $11.01 -$0.13
May 16, 2016 $11.14 $0.13
May 13, 2016 $11.01 $0.06
May 12, 2016 $10.95 -$0.11
View All

Distribution History7

Ex-Date Distribution Reinvest NAV
Dec 17, 2013 $0.06940 $10.78
No records in this table indicates that there has not been a distribution greater than .0001 within the past 3 years.
Fund prospectus

Capital Gain History7

Ex-Date Short-Term Long-Term Reinvest NAV
Dec 15, 2015 $0.15340 $1.01810 $11.82
Dec 16, 2014 $0.56450 $1.45310 $11.95
Dec 17, 2013 $0.19790 $1.16690 $10.78
No records in this table indicates that there has not been a capital gain greater than .0001 within the past 3 years.
Fund prospectus

Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is as of month-end for the stated time period only; due to market volatility, the Fund's current performance may be lower or higher than quoted. For the Eaton Vance Fund's performance as of the most recent month-end, please refer to eatonvance.com. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns shown at NAV unless noted otherwise. Returns for other classes of shares offered by the Fund are different. It is not possible to invest in an index.

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding. Fund invests in an affiliated investment company (Portfolio) with the same objective(s) and policies as the Fund. References to investments are to the Portfolio's holdings.

About Risk 

Fund performance is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, established companies. No Fund is a complete investment program and you may lose money investing in a Fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.


Portfolio

Asset Mix (%)4,8as of Mar 31, 2016

U.S. Common Stocks 76.10
Foreign Common Stocks 19.75
Cash 4.15
Total 100.00

Portfolio Statisticsas of Mar 31, 2016

Number of Holdings 40

Sector Breakdown (%)4as of Mar 31, 2016

Sector Fund MSCI World Health Care Index1
Biotechnology 34.35 17.23
Health Care Distributors 0.00 2.62
Health Care Equipment 13.48 9.90
Health Care Facilities 5.79 1.33
Health Care Services 2.42 3.59
Health Care Supplies 2.12 1.77
Health Care Technology 0.00 0.63
Life Sciences Tools & Services 3.63 3.29
Managed Health Care 2.29 6.67
Pharmaceuticals 31.78 50.98
Cash 4.15 0.00

Assets by Country (%)4as of Mar 31, 2016

United States 76.10
Japan 7.57
Switzerland 5.56
Denmark 2.21
Israel 1.94
Korea 1.52
Ireland 0.95
Cash & Other Assets 4.15
Total 100.00

Geographic Mix (%)4as of Mar 31, 2016

North America 76.10
Asia/Pacific 9.09
Europe 8.71
Middle East 1.94
Cash & Other Assets 4.15
Total 100.00

Fund Holdings (%)4,9as of Mar 31, 2016

Holding % of Net Assets
Ono Pharmaceutical Co Ltd 6.32%
Allergan plc 6.14%
HCA Holdings Inc 5.80%
AbbVie Inc 4.70%
Intuitive Surgical Inc 4.44%
Bristol-Myers Squibb Co 4.42%
Boston Scientific Corp 4.36%
Amgen Inc 4.06%
EV Cash Reserves Fund 4.04%
Regeneron Pharmaceuticals Inc 3.32%
View All

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding. Fund invests in an affiliated investment company (Portfolio) with the same objective(s) and policies as the Fund. References to investments are to the Portfolio's holdings.

About Risk 

Fund performance is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, established companies. No Fund is a complete investment program and you may lose money investing in a Fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.


Insights & Analysis

Commentary

A Word On The Markets as of Mar 31, 2016

After a reasonably orderly end to 2015, global equity markets started 2016 with extreme tumult and volatility. A significant sell-off to start the calendar year was primarily driven by macro factors.

Two primary concerns roiled global equities: The continued slowing of the Chinese economy and further declines in the price of oil. The resulting tumult created a "risk-off" environment in which investors fled the market and particularly sold high-flying, risky sectors, such as biotechnology.

While global equities stopped their dramatic swoon in February and partially rebounded in March, U.S. health care stocks slid further. The backdrop of rhetoric emanating from the U.S. presidential election cycle, in which drug pricing has been a hot-button topic, had not dissipated.

This was evident in the respective indexes. The MSCI World Index10 ended the quarter nearly flat, down 0.2% (total return). The MSCI World Health Care Index10 declined 6.8%. However, U.S. biotechnology stocks, as measured by the NASDAQ Biotechnology Index (NBI),11 fell almost 23% in the quarter.

Performance Summary 

Eaton Vance Worldwide Health Sciences Fund (the Fund) underperformed its benchmark, the MSCI World Health Care Index (the Index),1 for the quarter ended March 31, 2016, returning -11.24% for Class I shares at net asset value versus the Index's -6.82% return. Underperformance was due to sector positioning in biotechnology stocks, exacerbated by stock picking in specific biotechnology stocks that experienced precipitous share price declines triggered by negative catalysts.

  • Fund positioning within biotechnology in the first quarter was a notable overweight versus the Index. However, the NASDAQ Biotechnology Index11 fell 23% in the quarter, significantly impacting relative performance.
  • This was partially offset by the Fund's positioning in large-cap pharmaceutical stocks, where an underweight led to positive alpha generation.
  • Another key offsetting factor was stock selection in specialty pharmaceutical stocks, most notably in Japan and Korea.
  • Additional headwinds to relative performance came from stock selection in medical devices and life science tools.

Historic Returns (%)as of Mar 31, 2016

Annualized
1 Mo. 3 Mos. YTD 1 Yr. 3 Yrs. 5 Yrs. 10 Yrs.
Fund at NAV 2.49 -11.26 -11.26 -11.74 15.51 15.50 10.00
Fund w/Max Sales Charge -3.42 -16.38 -16.38 -16.79 13.25 14.15 9.35
MSCI World Health Care Index1 2.43 -6.82 -6.82 -8.28 11.85 14.45 8.14
Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund's current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative. Max Sales Charge: 5.75%.

Fund Factsas of Mar 31, 2016

Class A Inception 07/26/1985
Expense Ratio2 1.44%

Contributors 

Notable contributions to relative Fund performance in the quarter came almost exclusively from stock selection.

  • The most significant individual contributor was Ono Pharmaceutical Co. Ltd. The company's early launch of Opdivo for lung cancer in Japan surpassed company and investor expectations.
  • U.S. hospitals operator HCA Holdings Inc. outperformed on strong results for the fourth quarter of 2015 and initial 2016 guidance above expectations.
  • A more modest contribution came from Celltrion Inc. The Korea-based manufacturer of biosimilars gained the support of an FDA panel for its biosimilar of Johnson & Johnson's Remicade.
  • Share price gains for medical robotics manufacturer Intuitive Surgical, Inc. were driven by strong new system placements and expansion of procedures in new therapeutic categories.
  • Finally, shares of managed care provider WellCare Health Plans Inc. outperformed on positive 2017 Medicare reimbursement rates announced by CMS in February.

Detractors 

Performance detractors were significant during the quarter. The biotechnology sell-off was severe, and negative news was met with prompt, decisive selling.

  • The share price of biotech company Regeneron Pharmaceuticals fell more than 30% in the quarter. The launch of its novel cholesterol drug underwhelmed, while IP concerns about the same drug overwhelmed.
  • The share price of biotech company Portola Pharmaceuticals Inc. fell more than 60% after the company's lead pipeline product, betrixaban, failed in late-stage clinical trials.
  • The share price of biotech company Incyte Corp. fell more than 30% after data presented for its lead oncology product underwhelmed investors.
  • Litigation concerns pressured shares of Wright Medical Group NV, maker of orthopedic devices. The stock fell more than 30%.
  • The share price of biotech company Ophthotec Corp. Inc. fell more than 45%, as investors took profits following a strong run-up in the previous quarter.

Investment Outlook And Fund Positioning 

From a macro perspective, the market is caught in a crosscurrent between the looming presidential election and the next move by the U.S. Federal Reserve. Globally, emerging markets may have stabilized somewhat, but uncertainty over China's outlook persists. Oil prices may have bottomed in the first quarter, but the longer-term forecast remains cloudy.

In health care, all eyes will remain focused on the U.S. political landscape. In the near term, speculation over which candidates will win the presidential nominations will dominate the headlines. The risk associated with drug pricing may have abated somewhat, but the potential for legislation under a new president remains an issue.

Factors that could buoy biotech and pharmaceutical stocks going forward include potential mergers & acquisitions (M&A) and perhaps a return to fundamentals, such as clinical catalysts and new product launches.

Top 10 Holdings (%)3,4as of Mar 31, 2016

Ono Pharmaceutical Co Ltd 6.32
Allergan plc 6.14
HCA Holdings Inc 5.80
AbbVie Inc 4.70
Intuitive Surgical Inc 4.44
Bristol-Myers Squibb Co 4.42
Boston Scientific Corp 4.36
Amgen Inc 4.06
Regeneron Pharmaceuticals Inc 3.32
Biogen Inc 3.08
Total 46.62

No commentary information is currently available.

The views expressed in this report are those of portfolio manager(s) and are current only through the date stated at the top of this page. These views are subject to change at any time based upon market or other conditions, and Eaton Vance disclaims any responsibility to update such views. These views may not be relied upon as investment advice and, because investment decisions are based on many factors, may not be relied upon as an indication of trading intent on behalf of any Eaton Vance fund. This commentary may contain statements that are not historical facts, referred to as "forward looking statements". The Fund's actual future results may differ significantly from those stated in any forward-looking statement, depending on factors such as changes in securities or financial markets or general economic conditions, the volume of sales and purchases of Fund shares, the continuation of investment advisory, administrative and service contracts, and other risks discussed from time to time in the Fund's filings with the Securities and Exchange Commission.

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding. Fund invests in an affiliated investment company (Portfolio) with the same objective(s) and policies as the Fund. References to investments are to the Portfolio's holdings.

About Risk 

Fund performance is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, established companies. No Fund is a complete investment program and you may lose money investing in a Fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.

Attribution

No attribution information is currently available.

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding. Fund invests in an affiliated investment company (Portfolio) with the same objective(s) and policies as the Fund. References to investments are to the Portfolio's holdings.

About Risk 

Fund performance is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, established companies. No Fund is a complete investment program and you may lose money investing in a Fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.


Management

Biography
Samuel D. Isaly

Samuel D. Isaly

Founder and Managing Partner
OrbiMed Advisors LLC
Founded OrbiMed 1989

Sam Isaly is founding principal of OrbiMed Advisors LLC, a New York- based Eaton Vance investment adviser.

Sam has been active in international and health care investing throughout his career, beginning at Chase Manhattan Bank in 1968. In 1982, his company, Gramercy Associates, was the first to develop an integrated, worldwide system of analysis on the 100 leading pharmaceutical companies, with investment recommendations conveyed to 30 leading financial institutions in the U.S. and Europe. Gramercy Associates was absorbed into S.G. Warburg & Co., Inc., in 1986, where he was senior vice president and international equity analyst. For a time, Sam was also associated with Credit Suisse as an analyst of the European pharmaceutical industry. In all, he has worked as a pharmaceutical and international investment specialist for more than three decades. In July of 1989, Sam co-founded a predecessor organization to OrbiMed Advisors, an Eaton Vance investment adviser.

Sam earned a B.A. from Princeton University and a M.Sc. in economics from the London School of Economics. He is a native of Youngstown, Ohio and has lived in New York City since 1968, with the exception of 1974–1977, when he lived in Paris, France.

Sam's commentary has appeared in the Associated Press, Barron's, Barron's Online, Bloomberg, CNNfn.com, Forbes Global, Investor's Business Daily, The Miami Herald, The New York Times, The Sacramento Bee, SmartMoney, USA Today, The Wall Street Journal, and he has been featured on CNBC.

Education
  • B.A. Princeton University
  • M.Sc. London School of Economics
Experience
  • Managed Fund since 1989
 
Biography

Sven H. Borho, CFA

General Partner
OrbiMed Advisors LLC
Joined OrbiMed 1991

Sven Borho is a founding general partner of OrbiMed Advisors LLC, a New York-based Eaton Vance investment adviser. He is a portfolio manager for Orbimed's public equity funds and heads the firm's trading efforts.

Sven started his career in 1991 when he joined Mehta and Isaly as a senior analyst covering European pharmaceutical firms and biotechnology companies worldwide. In 1993, he became portfolio manager.

Sven studied business administration at Bayreuth University in Germany and earned a M. Sc. (Econ.) from The London School of Economics. He is a CFA charterholder. He is a citizen of both Germany and Sweden.

Education
  • Bayreuth University
  • M.Sc. London School of Economics
Experience
  • Managed Fund since 2005
 
Biography

Geoffrey C. Hsu, CFA

General Partner
OrbiMed Advisors LLC
Joined OrbiMed 2002

Geoffrey Hsu is a general partner of OrbiMed Advisors LLC, a New York-based Eaton Vance investment adviser.

Prior to joining OrbiMed in 2002 as a biotechnology analyst, Geoffrey worked as a financial analyst in the health care investment banking group at Lehman Brothers and served as manager of business development at Veritas Medicine.

Geoffrey earned an A.B., summa cum laude, from Harvard University and an M.B.A. from Harvard Business School. Prior to business school, he spent two years studying medicine at Harvard Medical School. He is a CFA charterholder.

Education
  • A.B. Harvard College
  • M.B.A. Harvard Business School
Experience
  • Managed Fund since 2005
 
Biography

Richard D. Klemm, Ph.D., CFA

Biotechnology Analyst
OrbiMed Advisors LLC
Joined OrbiMed 2000

Richard Klemm is a public equity analyst at OrbiMed Advisors LLC, a New York-based Eaton Vance investment adviser.

Richard joined OrbiMed in 2000 as a public biotechnology company analyst.

Richard earned a B.A. from the University of California, Berkeley in 1994 with majors in molecular and cell biology and economics. Dr. Klemm completed a Ph.D. from the Massachusetts Institute of Technology in molecular biology in 2000, and has published scientific articles in the fields of DNA replication and transcription. He is a CFA charterholder.

Education
  • B.A. University of California, Berkeley
  • Ph.D. Massachusetts Institute of Technology
Experience
  • Managed Fund since 2005
 
Biography

Trevor M. Polischuk, Ph.D.

Global Pharmaceutical Analyst
OrbiMed Advisors LLC
Joined OrbiMed 2003

Trevor Polischuk is a public equity analyst at OrbiMed Advisors LLC, a New York-based Eaton Vance investment adviser.

Trevor joined OrbiMed in 2003 as an analyst covering the major global pharmaceutical industry. Previously, he worked at Lehman Brothers as a senior research analyst covering the U.S. pharmaceutical industry. Dr. Polischuk began his career at Warner Lambert as a member of the Pharmaceutical Global Marketing Planning team. In this role, he coordinated marketing activities for the second generation gabapentinoid product, Pregabalin.

Trevor holds a doctorate in neuropharmacology & gross human anatomy and an M.B.A. from Queen's University.

Education
  • Ph.D. and M.B.A Queen's University
Experience
  • Managed Fund since 2005
 

Literature

Literature

Fact Sheet

Commentary

Annual Report

Full Prospectus

Holdings-1st or 3rd fiscal quarters-www.sec.gov

Proxy Statement

SAI

Semi-Annual Report

Summary Prospectus

XBRL


 

loading

We apologize for the inconvenience but we are experiencing a technical issue.

We are working on a solution. Please try again later.

If you require further assistance, please call:
1-800-836-2414.

You have already upgraded your account. Please login using the link at the top of the page.

    Your download will begin when this window is closed.

    You have successfully un-subscribed from .

    As a subscriber, you are one step away from getting more access and control. Register now by simply creating a password below.

    Passwords must be 8 to 20 alphanumeric characters, including a special character:
    ! @ # $ % ^ & * ( ) - _ = + , < . > ?.

    Cancel

    Trouble registering? Call 1-800-836-2414.

    Congratulations! You are registered.

    We have sent a verification email to . Please check your e-mail and click on the secured link to verify your account and complete the registration process.

    Trouble receiving the verification email? Call 1-800-836-2414.

    Congratulations!

    We are pleased to grant you access to this Eaton Vance website.

    Please click here to be logged in with your username .

    A verification email has been sent.

    You have requested a change to your password. In order to process this request, a verification email has been sent to . When you receive this email, please click the link contained within the email to start the password reset process.

    Trouble signing in? Call 1-800-836-2414.

    This account is restricted.

    Your account has limited access. You currently have access to content for:

    Firm restriction.

    This document has not been approved at your firm. We can not complete your subscription request at this time. Please try again later.


    If you need further assistance, please call 1-800-836-2414.

    This account has been updated.

    Your account has been updated to use your new email address .

    We have sent a verification email to with a verification link to confirm the change.

    Trouble receiving the verification email? Call 1-800-836-2414.

    This email account has not been verified.

    Your account has not yet been activated. We have sent a verification email to . If you'd like us to resend this, please click the Resend Email button below.

    Trouble receiving the verification email? Call 1-800-836-2414.

    Cancel

    Thank you.

    An e-mail verification has been re-sent to . Please check your e-mail and follow the instructions to complete the registration process.

    Trouble receiving the verification email? Call 1-800-836-2414.

    An email has been sent to the email address containing a link to verify your credentials. Please check your e-mail and click on the secured link to complete your request.

    Trouble receiving the verification email? Call 1-800-836-2414.

    Re-verification Required

    For security purposes we could not complete your request. Please click here to receive a new link to access the requested content.

    A new email has been sent to the email address containing a link to re-verify your credentials. Please check your e-mail and click on the secured link to complete your request.

    Trouble receiving the verification email? Call 1-800-836-2414.

    Verification Accepted

    You have been granted access to the requested content.

    Remember Me

    Click here to remain recognized on this device for future visits to EatonVance.com

    Do Not Remember Me

    Click here if you are using a Public Computer or Shared Device.

    Trouble receiving the verification email? Call 1-800-836-2414.

    Cancel

    Subscribe to new content: Register

    Please check the Fund Literature that you would like to subscribe to. Your subscriptions can be managed on your profile page.

    Subscribe All

    Thank you for downloading

    If your download did not start automatically, please click here.

    Stay on top of your game.

    Receive email notifications when the  is updated by clicking the subscribe button.

    Close

    Thank you for subscribing

    We have sent a verification email to . Please check your e-mail and click on the secured link to verify your subscription.

    Un-subscription request

    We have sent a verification email to . Please check your e-mail and click on the secured link to verify your request.

    Stay on top of your game.

    You have selected to receive email notifications for:

    Cancel

    Subscribe to new content: Register

    Stay on top of your game.

    You are currently "Opted Out" of all Eaton Vance email communications. If you would like to be alerted of updates to your new subscription, please Opt In:

    Close

    Enter your e-mail address to reset your password.

    Already have an account?
    Subscribe to new content: Register

    Trouble registering? Call 1-800-836-2414.

    Simply enter your e-mail address to register.

    Cancel

    Already have an account?

    Register for more access and control.
    • Elevate your business practice with materials from the Advisor Institute.
    • Learn more with exclusive videos, conference calls, and the latest insights.
    • Follow products, get product notifications, and manage your Eaton Vance communications.
    Please wait while the data is being prepared for download.
    loading
    This message will automatically close when your file is ready.
    Please enter a new email.

    Trouble signing in? Call 1-800-836-2414.

    Investment Professionals

    Register Now

    Already have an account? .

     

    Symbol:  

    NAV as of